Investigating the Impact of Drug Crystallinity in Amorphous

  • Slides: 9
Download presentation
Investigating the Impact of Drug Crystallinity in Amorphous Tacrolimus Capsules on Pharmacokinetics and Bioequivalence

Investigating the Impact of Drug Crystallinity in Amorphous Tacrolimus Capsules on Pharmacokinetics and Bioequivalence Using Discriminatory In Vitro Dissolution Testing and Physiologically Based Pharmacokinetic Modeling and Simulation Hitesh S. Purohit, Niraj S. Trasi, Dajun D. Sun, Edwin C. Y. Chow, Hong Wen, Xinyuan Zhang, Yi Gao, Lynne S. Taylor JPharm. Sci Volume 107 Issue 5 Pages 1330 -1341 (May 2018) DOI: 10. 1016/j. xphs. 2017. 12. 024 Copyright © 2018 American Pharmacists Association® Terms and Conditions

Figure 1 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024)

Figure 1 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024) Copyright © 2018 American Pharmacists Association® Terms and Conditions

Figure 2 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024)

Figure 2 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024) Copyright © 2018 American Pharmacists Association® Terms and Conditions

Figure 3 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024)

Figure 3 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024) Copyright © 2018 American Pharmacists Association® Terms and Conditions

Figure 4 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024)

Figure 4 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024) Copyright © 2018 American Pharmacists Association® Terms and Conditions

Figure 5 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024)

Figure 5 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024) Copyright © 2018 American Pharmacists Association® Terms and Conditions

Figure 6 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024)

Figure 6 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024) Copyright © 2018 American Pharmacists Association® Terms and Conditions

Figure 7 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024)

Figure 7 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024) Copyright © 2018 American Pharmacists Association® Terms and Conditions

Figure 8 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024)

Figure 8 JPharm. Sci 2018 1071330 -1341 DOI: (10. 1016/j. xphs. 2017. 12. 024) Copyright © 2018 American Pharmacists Association® Terms and Conditions

POLYMER CRYSTALLINITY The amorphous nature of polymers isPOLYMER CRYSTALLINITY The amorphous nature of polymers is
Amorphous State An amorphous polymer does not exhibitAmorphous State An amorphous polymer does not exhibit
MIT 3 071 Amorphous Materials 11 Amorphous SiliconMIT 3 071 Amorphous Materials 11 Amorphous Silicon
Photoluminescence of Amorphous Silicon Overview l l AmorphousPhotoluminescence of Amorphous Silicon Overview l l Amorphous
Noncrystalline Amorphous Structures Prabhjot Singh Noncrystalline Amorphous StructuresNoncrystalline Amorphous Structures Prabhjot Singh Noncrystalline Amorphous Structures
Dust crystallinity and the evolution of dusty disksDust crystallinity and the evolution of dusty disks
Chapter 22 SKKU Physical Pharmacy Laboratory polymorphism crystallinityChapter 22 SKKU Physical Pharmacy Laboratory polymorphism crystallinity
MOLECULAR WEIGHT CRYSTALLINITY Molecular weight Mw Mass ofMOLECULAR WEIGHT CRYSTALLINITY Molecular weight Mw Mass of